Nova Anchora
Developing a corrective topical biologic therapy for Dystrophic Epidermolysis Bullosa (DEB)
An Overview of DEB
DEB is a rare, genetic skin disease — a particularly debilitating form of Epidermolysis Bullosa (EB), which is sometimes called “butterfly disease” due to the fragility of patients’ skin (similar to butterfly’s wings).
In affected individuals, collagen VII (C7) — a protein that forms “anchoring fibrils” that attach the skin’s outer protective layer (epidermis) — is not functioning correctly. As a result, even light rubbing of the skin can cause blistering or tearing, frequently causing open wounds to form and persist.
Nova Anchora’s approach
Nova Anchora is advancing NvA-021, an investigative therapeutic gel designed to apply to patients’ wounds during normal bandage changes. NvA-021 contains a genetically corrected version of C7. The NvA program holds an exclusive license from Stanford University for technology designed to ensure the stability of manufactured C7.
In relation to existing approved treatments, NvA-021 is being developed to, in particular, address treatment gaps and enhance ease-of-use.
Current development status
Nova Anchora has received Pre-IND feedback from the FDA, and is initiating studies that enable clinical trials. The FDA has also granted Nova Anchora Orphan Drug and Rare Pediatric special designations.
Company leadership
-
Jason Bhardwaj
CEO, Co-Founder
20+ years in healthcare and biotech leadership; Duke Biomedical B.S.E., Harvard M.B.A. Previously CEO Follica (Derm Pre-IND to Ph3-ready); Tal Medical, Medtronic, Bain & Company
-
Dr. Peter Marinkovich
Chair of SAB, Co-Founder
Associate Professor of Dermatology at Stanford, Faculty of Epithelial Biology and Cancer Biology. Key Opinion Leader in the EB field. Primary investigator for several clinical programs, including Vyjuvek (B-VEC) for Krystal Bio
